Log in to your Inderes Free account to see all free content on this page.
Diagonal Bio
0.026
SEK
+5.31 %
DIABIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+5.31%
-25.22%
+100%
-16.5%
-87.94%
-89.36%
-99.25%
-
-99.52%
Diagonal Bio operates in the biotechnology industry. The company is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service and associated ancillary services are also offered. The largest operations take place in Sweden with headquarter in Lund.
Read moreMarket cap
10.34M SEK
Turnover
18.89K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
25.2.
2025
Annual report '24
14.5.
2025
Interim report Q1'25
20.5.
2025
General meeting '24
ShowingAll content types
Diagonal Bio AB: Nomination Committee appointed for Diagonal Bio
Diagonal Bio AB: Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio